ScienceBank

DOI: 10.61340/VNVA9232
Submitted: 13 April 2024
Accepted after peer review: 16 August 2024
Published: 3 September 2024

✦ Review article

Stem Cell-Nanodiamond Synergy: Efficacy in Breast Cancer

Dito Anurogo[1, 2] and Taruna Ikrar[3, 4, 5, 6*]

1. International PhD Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Address: No. 250, Wuxing Street, Xinyi District, Taipei City, 110, Tel: 02-2736-1661.
2. Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Sultan Alauddin 259th street, Gunung Sari, Rappocini, Makassar city, South Sulawesi, 90221, Indonesia
3. Fakultas Kedokteran Universitas Pertahanan Republik Indonesia, Bogor Jawa Barat, Indonesia. Kawasan IPSC Sentul, Sukahati, Kec. Citeureup, Kabupaten Bogor, Jawa Barat 16810, Indonesia
4. Universitas Malahayati, Bandar Lampung, Indonesia, Jl. Pramuka No.27, Kemiling Permai, Kec. Kemiling, Kota Bandar Lampung, Lampung, 35152, Indonesia
5. Indonesian Medical Council (Konsil Kedokteran Indonesia) Jl. Teuku Cik Ditiro No.6 9, RT.9/RW.2, Gondangdia, Kec. Menteng, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10350, Indonesia
6. The Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan, BPOM) Official Address: Jalan Percetakan Negara Nomor 23, Jakarta - 10560 - Indonesia

*** Corresponding author**: Prof. Dr. Taruna Ikrar, M.D., PhD. Adjunct Professor of Medicine, Faculty of Military Medicine, The Republic of Indonesia Defense University. Kawasan IPSC Sentul, Sukahati, Kec. Citeureup, Kabupaten Bogor, Jawa Barat 16810, Indonesia. Email: dr.ikrar.phd@gmail.com

Keywords: stem cell dynamism, nanodiamond versatility, breast cancer therapeutics, integrative oncology, advanced drug delivery modalities, regenerative oncology, nano-bio interface

Abstract

In the intricate and evolving landscape of oncological research and therapeutic modalities, the imperative for sophisticated, precise, and holistic strategies becomes paramount, especially within the intricate realm of breast cancer management. This analytical discourse undertakes a comprehensive examination of the synergistic interplay between stem cells and nanodiamonds, unveiling their collective potential to pioneer transformative therapeutic paradigms. Within the confines of this discussion, stem cells are acknowledged for their intrinsic adaptability and potent regenerative properties, whereas nanodiamonds are recognized for their versatile functions in targeted drug delivery systems and their inherent biocompatibility. Individually, they embody diverse therapeutic prospects; however, it is their collaborative interaction that is positioned at the vanguard of this evaluative discourse. The elaborate biophysical and biochemical exchanges incited by the

amalgamation of stem cells' regenerative prowess and nanodiamonds' precision in drug conveyance are meticulously analyzed. This analysis transcends conventional scrutiny, delving into the profound molecular mechanisms, cellular kinetics, and resultant clinical ramifications, thereby delineating a comprehensive blueprint for an integrated therapeutic strategy.

Graphical Abstract

Stem Cells
(ESCs, ASCs, iPSCs)

Nanodiamonds
(Biocompatible, surface-modified)

Synergistic Effect
- Targeted drug delivery
- Tumor homing
- Controlled release
- Enhanced proliferation
- Reduced side effects

Created by Dito Anurogo with generative AI tools

Introduction

Breast cancer poses a significant challenge due to its heterogeneity and complex origins, making the demand for more effective treatments urgent as its incidence rises.[1] Traditional therapies like chemotherapy, radiation, and targeted therapy, although useful, often fall short of addressing the intricate needs of breast cancer treatment. Chemotherapy and radiation, while effective at killing cancer cells, also damage healthy cells, leading to significant side effects such as hair loss, fatigue, and increased infection risk.[2,3] Targeted therapies, which aim to block specific molecules involved in cancer growth, can develop resistance over time and may not be effective for all patients.[4] These limitations prompt a shift towards more sophisticated and targeted methods.

Innovative treatments, such as the synergy between stem cells and nanodiamonds, offer promising advancements over conventional methods. Stem cells, known for their regenerative abilities and flexibility, are potential candidates for cancer treatment, offering not just tissue repair but also targeted therapy delivery.[5] Nanodiamonds, recognized for their unique properties and biocompatibility, provide a novel means for drug delivery and imaging, contributing significantly to cancer treatment.[6] By combining stem cells' regenerative power with nanodiamonds' delivery precision, this approach seeks to enhance treatment effectiveness and specificity while reducing side effects. This novel method not only addresses the shortcomings of traditional treatments but also holds potential for significantly improving patient outcomes in breast cancer therapy by offering a more targeted and efficient approach. The following sections will explore these aspects further, shedding light on an integrated and improved approach to breast cancer therapy.

Methods

The information was compiled using a systematic literature review methodology. Articles were selected based on relevance, impact factor, and recency, utilizing regenerative AI tools for comprehensive database searches.

Stem Cells: The Regenerative Vanguard

Nature and Types of Stem Cells Relevant to Oncology

Stem cells, central to regenerative innovation, are pivotal in oncology due to their differentiation abilities and self-renewal.[7] In cancer research, embryonic stem cells (ESCs) and adult stem cells (ASCs) are particularly relevant.[8] ESCs offer wide-ranging differentiation potential, while ASCs, found throughout the body, present fewer ethical issues and reduced immune response risks.[9] Induced pluripotent stem cells (iPSCs), reprogrammed to exhibit embryonic traits, are noteworthy for their customizability in therapy.[10]

The study of cancer stem cells (CSCs), a tumor-based subset with stem-like properties, has reshaped our understanding of cancer growth and dissemination.[11, 12] Targeting the self-renewing and differentiating capacities of CSCs is crucial for effective and sustainable cancer therapies.[13] Additionally, leveraging stem cells for oncolytic virus delivery and gene therapy represents an advanced cancer treatment frontier.[14] These methods utilize stem cells' natural tumor-homing ability to deliver treatments precisely, reducing potential toxicity.[15]

As research progresses, merging stem cell technology with fields like immunotherapy and nanotechnology heralds a future of precision oncology.[16, 17, 18] This approach aims to customize treatment based on the distinct genetic and molecular profiles of individual cancers, advancing towards more effective and personalized care.

Mechanisms of Stem Cell-Induced Regeneration

The complex mechanisms of stem cell-induced regeneration are critical to tissue repair and rejuvenation.[19] Stem cells aid in regeneration via direct differentiation into specific cell types to replace damaged ones, secretion of paracrine factors that facilitate healing and engage local cells in repair, and modulation of the immune response to enhance the regenerative microenvironment.[20, 21, 22] These processes are governed by intricate signaling pathways and genetic controls, ensuring precise responses to tissue needs.[23]

Further, stem cells possess an innate ability to migrate to injury or disease sites, directed by inflammatory signals and the unique chemical environment of the affected tissue.[24] At the damage site, they engage in biochemical communication with local cells, promoting repair and integration.[25] This interaction is vital for the successful remodeling and assimilation of new cells into existing tissue structures.[22] The extracellular matrix (ECM) also plays a crucial role by providing structural support and signals necessary for stem cell differentiation and integration.[26]

Advances in understanding these mechanisms are driving the development of sophisticated regenerative strategies that combine stem cells, scaffolds, and bioactive molecules for improved tissue repair and replacement.[27, 28] Ongoing research into these complex processes holds the promise of unlocking new potential for stem cell therapies across various degenerative conditions and injuries, offering new avenues for restoration where conventional treatments have limitations.[29]

Stem Cells in Cancer Treatment: Current State and Limitations

Stem cell application in oncology is a rapidly evolving field, characterized by significant potential and notable challenges. Presently, the mainstay of stem cell-based oncology treatments is hematopoietic stem cell transplantation for treating blood cancers, which has become a lifesaving option for numerous patients.[30, 31] Yet, extending these applications to solid tumors and other cancer types entails overcoming substantial obstacles. Critical among these are ensuring precise stem cell delivery to tumors and mitigating risks like the inadvertent promotion of tumor growth.[32] Moreover, ethical concerns, especially regarding embryonic stem cells (ESCs), and the technical intricacies involved in stem cell manipulation and transplantation add to the complexity of this field.[15, 33]

Despite these hurdles, the prospects for stem cell utilization in cancer therapy remain promising. Research is continuously advancing, revealing innovative ways to exploit stem cells, such as engineering them to target and eliminate cancer cells or using them as vectors for specific drug delivery.[34, 35] As our comprehension of these mechanisms expands and technological capabilities advance, today's challenges are expected to give rise to tomorrow's revolutionary therapies. This progression is setting the stage for stem cells to lead the regenerative battle against cancer, marking a new frontier in therapeutic development.

Breast Cancer Stem Cells

Breast cancer stem cells (BCSCs) play a crucial role in tumor initiation, maintenance, resistance to therapies, and relapse due to their self-renewal and differentiation properties, contributing to tumor heterogeneity. Key regulatory pathways include Notch, Hedgehog, Wnt/β-catenin, and PI3K/Akt, promoting tumor growth and resistance.

Therapeutic targets involve specific pathways and surface markers (CD44+/CD24−), employing small molecules, antibodies, CAR-T cells, differentiation therapy, and EMT inhibition. BCSCs exhibit drug resistance through multidrug resistance genes and efflux transporters, surviving conventional therapies and leading to relapse. Innovative therapies include genetically modified hematopoietic stem cells, mesenchymal stem cells, and human amniotic membrane-derived epithelial stem cells. Current clinical trials focus on targeting BCSCs, aiming to refine strategies, understand BCSC biology, and develop novel treatments for improved patient outcomes (see Table 1 for details).

Table 1. Key aspects of breast cancer stem cells (BCSCs) in therapy and clinical trials

Aspect	Details	References
Role of Breast Cancer Stem Cells (BCSCs)	BCSCs are implicated in tumor initiation, maintenance, resistance to therapies, and relapse. They possess properties like self-renewal and differentiation, contributing to tumor heterogeneity and treatment resistance.	36, 37, 38
Signaling Pathways in BCSCs	Key signaling pathways involved in the regulation of BCSCs include Notch, Hedgehog, Wnt/β-catenin, and PI3K/Akt. These pathways contribute to the self-renewal and differentiation of BCSCs, promoting tumor growth and resistance.	39, 40, 41
Therapeutic Targets	Targeting specific pathways (Notch, Wnt, Hedgehog) and surface markers (CD44+/CD24−) on BCSCs. Use of small molecules, antibodies, and CAR-T cells to target these pathways and markers. Strategies also include differentiation therapy and inhibition of EMT.	42, 43, 44
Drug Resistance	BCSCs contribute to drug resistance through expression of multidrug resistance genes and drug efflux transporters. They can also survive conventional chemotherapy and radiotherapy, leading to relapse and metastasis.	38, 45
Innovative Therapies	Use of genetically modified hematopoietic stem cells for controlled tumor stroma degradation, mesenchymal stem cells for targeted therapy, and human amniotic membrane-derived epithelial stem cells for anticancer activity.	46, 47, 48
Clinical Trials and Future Directions	Current clinical trials are assessing the efficacy of agents targeting BCSCs. Future directions include refining therapeutic strategies, understanding BCSC biology, and developing novel treatments to effectively target BCSCs to improve patient outcomes.	49, 50, 51

Clinical Trials of Stem Cells in Breast Cancer Management

Phase I/II clinical trials have investigated stem cells for targeted breast cancer therapy, using them as therapeutic agents or directly targeting cancer stem cells (CSCs). High-dose chemotherapy with autologous stem cell transplants improves relapse-free survival but not overall survival. Targeted therapies (small molecules, antibodies, CAR-T cells) are being tested for efficacy against BCSCs.

Understanding BCSC resistance mechanisms is critical for developing effective therapies. Gene therapy with genetically modified hematopoietic stem cells shows promise. Biomarkers are essential for evaluating novel therapies in clinical trials. Novel approaches target BCSC pathways (Wnt, Notch, Hedgehog) and natural compounds. Innovative trial designs are needed to assess therapy impacts. Challenges include tumor heterogeneity and identifying biomarkers. The CXCL8-CXCR1/2 axis is targeted in phase II trials with promising results (see Table 2 for details).

Table 2. Key aspects of clinical trials in stem cell-based breast cancer management

Aspect	Details	References
Phase I/II Clinical Trials	Multiple phase I and II clinical trials have investigated the use of stem cells for targeted therapy in breast cancer. Some trials use stem cells as vehicles for therapeutic agents, while others target cancer stem cells directly.	52
High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplant	HDC with autologous stem cell transplant has been tested for stage IV breast cancer with minimal metastases. This approach showed promise in improving relapse-free survival but did not significantly impact overall survival.	53, 54, 55
Targeted Therapies in Clinical Trials	Targeted therapies, including small molecules, antibodies, and CAR-T cells, have been developed to target breast cancer stem cells (BCSCs). Clinical trials are underway to assess their efficacy in combination with conventional therapies.	41, 44
Mechanisms of Resistance	BCSCs are resistant to current chemotherapy and radiation, making it imperative to understand their mechanisms of resistance to develop effective therapeutic strategies.	38, 45
Stem Cell Gene Therapy	Gene therapy using genetically modified hematopoietic stem cells has been proposed for controlled tumor stroma degradation, showing promising results in preclinical models.	46
Biomarkers for Clinical Trials	The identification and use of biomarkers are crucial for assessing the efficacy of novel therapies targeting cancer stem cells in clinical trials.	56, 57

Novel Therapeutic Approaches	Novel approaches, such as targeting BCSC- specific pathways (e.g., Wnt, Notch, Hedgehog) and using natural compounds, are being explored in clinical trials to improve treatment outcomes.	42, 58
Clinical Trial Design	Innovative clinical trial designs are necessary to assess the impact of new therapies on cancer stem cells and to measure clinical endpoints effectively.	37
Challenges and Future Directions	Challenges include tumor heterogeneity and identifying suitable biomarkers for targeting BCSCs. Future directions involve integrating stem cell-based therapies with conventional treatments for better outcomes.	43, 50, 59
CXCR1/2 Axis in Clinical Trials	The CXCL8-CXCR1/2 axis is being targeted in breast cancer stem-like cells, with ongoing randomized, double-blind phase II clinical trials showing promising preclinical and clinical results.	60

Safety and Efficacy of Stem Cell Therapy and Nanotechnology in Breast Cancer Management

High-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (AHSCT) shows significant benefits in recurrence-free survival for HER2-negative and triple-negative breast cancer. A phase I trial confirmed that the STEMVAC vaccine is safe, eliciting significant T-cell immunity in HER2-negative advanced breast cancer. Reviews highlight the potential of targeting breast cancer stem cells (BCSCs) to overcome therapy resistance and metastasis. Experimental studies show that co-delivery systems targeting ABCG2 and BCL2 genes enhance chemotherapy efficacy against BCSCs with no severe side effects. Long-term follow-up indicates that HDCT improves survival in high-risk patients with ≥10 involved axillary lymph nodes, though it presents a similar long-term risk for secondary malignancies and cardiovascular events (see Table 3 for details).

Table 3. Safety and efficacy of stem cell therapy in breast cancer management

Study Title	Authors (Year)	Study Type	Key Findings	Safety Profile	Ref.
High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer	Pedrazzoli et al. (2015)	Meta-analysis	HDC with stem cell support shows benefit in recurrence-free survival for HER2-negative and triple-negative breast cancer	Safe with adequate stem cell support	61

A phase I trial of the safety and immunogenicity of a multiple antigen vaccine (STEMVAC) in HER2 negative advanced stage breast cancer patients	Higgins et al. (2016)	Phase I trial	STEMVAC vaccine is safe and elicits significant T-cell immunity in HER2-negative breast cancer patients	No dose-limiting toxicity observed	62
Breast cancer stem cells: Biology and therapeutic implications	Butti et al. (2019)	Review	Targeting cancer stem cells could improve treatment outcomes by addressing therapy resistance and metastasis	N/A	38
Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance	Palomeras et al. (2018)	Review	BCSCs are responsible for therapy resistance and targeting them can improve treatment efficacy	N/A	44
Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense	Sun et al. (2015)	Experi-mental study	Co-delivery system targeting ABCG2 and BCL2 genes enhances chemotherapy efficacy against breast cancer stem cells	No severe side effects reported	63
High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up	Steenbruggen et al. (2020)	Long-term follow-up study	HDCT provides improved survival in very high-risk patients with ≥10 involved axillary lymph nodes	Similar long-term risk for second malignancy and cardiovascular events	64

Nanotechnology offers significant advancements in breast cancer management by reducing chemotherapy side effects and enhancing therapeutic efficacy. Active targeting nanoplatforms like gold, silica, and iron oxide nanoparticles improve diagnosis and treatment precision.

Nanoparticles enhance targeted delivery of anticancer drugs, reducing toxicity and improving therapeutic efficiency. Nanomaterials significantly advance detection, diagnosis, and treatment over conventional methods. Nanoparticles can deliver immunotherapeutics, enhancing T-cell responses and modulating the tumor microenvironment. They also improve targeting and visualization of metastasis, enhancing chemotherapy and immunotherapy efficacy. Multifunctional gold nanoparticles enhance drug delivery and reduce side effects, offering effective solutions for drug resistance and side effects in breast cancer therapy (see Table 4 for details).

Table 4. Safety and efficacy of nanotechnology in breast cancer management

Study Title	Authors (Year)	Study Type	Key Findings	Safety Profile	Ref.
Nanotechnology Approaches for Prevention and Treatment of Chemotherapy-Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors	Nevins et al. (2023)	Review	Nanoparticles show potential in reducing side effects of chemotherapeutics while improving efficacy	Requires further research for safety	65
New Advances in Nanotechnology Based Diagnosis and Therapeutics for Breast Cancer	Falagan-Lotsch et al. (2017)	Review	Active targeting nanoplatforms like gold, silica, and iron oxide nanoparticles improve diagnosis and treatment efficacy	Generally safe, but requires clinical validation	66
Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment	Tran et al. (2019)	Review	Nanoparticles improve targeted delivery of anticancer drugs, enhancing therapeutic efficiency and reducing toxicity	Generally safe with targeted delivery	67
How can nanotechnology help the fight against breast cancer?	Avitabile et al. (2018)	Review	Nanomaterials enhance detection, diagnosis, and treatment, offering significant advancements over conventional methods	Further research needed for clinical translation	68

Nanotechnology Applications in Breast Cancer Immunotherapy	Wang et al.(2023)	Review	Nanoparticles can deliver immunotherapeutics to enhance T-cell responses and modulate tumor microenvironment	Safe in preclinical studies	69
Nanoparticles for imaging and treatment of metastatic breast cancer	Mu et al. (2017)	Review	Nanoparticles improve targeting and visualization of metastasis, enhancing chemotherapy and immunotherapy efficacy	Safe with controlled targeting	70
Recent Advances in Nanotechnology for Breast Cancer Therapy	Qin et al. (2019)	Review	Nanomaterials offer effective solutions for drug resistance and side effects in breast cancer therapy	Safe with targeted approach	71
Optimization of anti-cancer drugs and a targeting molecule on multifunctional gold nanoparticles	Rizk et al. (2016)	Experi-mental study	Multifunctional gold nanoparticles improve drug delivery and reduce side effects in breast cancer therapy	Safe with enhanced targeting	72

Nanodiamonds: Facets of Versatility

Properties and Types of Nanodiamonds

Nanodiamonds, small-sized diamonds of a few nanometers, are a nanotechnology marvel with a vast array of applications in science and medicine, particularly in oncology.[73] Their exceptional hardness, expansive surface area, and ease of surface modification make them ideal for biomedical uses. There are various types, including detonation nanodiamonds, created through explosive techniques, and high-pressure high-temperature nanodiamonds, formed under extreme conditions. Each variety offers unique attributes in terms of purity, size, and surface chemistry, allowing for customized applications.[74, 75]

Characterized by their biocompatibility and non-toxicity, nanodiamonds are particularly suited for

health-related applications. Their surfaces can be modified to transport various therapeutic agents, imaging probes, and biomolecules, enhancing their utility in targeted drug delivery and bioimaging. Their optical characteristics, like fluorescence and Raman scattering, provide valuable tools for cellular and molecular imaging, advancing our understanding of biological systems and pathologies. Beyond medicine, nanodiamonds are utilized in electronics and industry for their thermal and electron emission properties.

As research evolves, the scope of nanodiamond applications continues to broaden, promising groundbreaking advancements in cancer therapy and the development of innovative nanoscale devices, marking them as a key player in the future of nanotechnology and medical science.[76, 77, 78]

Nanodiamonds in Drug Delivery: Mechanisms and Advantages

Nanodiamonds play a pivotal role in drug delivery, showcasing their diverse capabilities. Their extensive surface area supports the adsorption of numerous therapeutic agents, and their modifiable surface enhances drug loading and precision targeting. Specifically, nanodiamonds can be tailored to bind with certain drugs, promoting controlled release and direct delivery to cancerous cells, thereby sparing healthy tissues and reducing adverse effects. The delivery process typically involves the attachment of drugs to the nanodiamond surface, facilitating targeted release at the intended site.[79]

The benefits of utilizing nanodiamonds for drug delivery are extensive. They enhance the stability and bioavailability of drugs, increase the solubility of hydrophobic substances, and allow for the loading of multiple drugs, positioning them as a potent tool against cancer.[80]

Their biocompatibility and low toxicity are crucial, minimizing immunogenic and cytotoxic responses often associated with synthetic carriers. The adjustable release profiles of nanodiamonds provide precise control over drug release timing, improving therapeutic efficacy. The customization potential of nanodiamonds supports the simultaneous delivery of various drugs or diagnostic agents, leading to synergistic treatments and personalized therapies. Additionally, their unique optical properties enable real-time tracking and imaging of drug delivery, improving the accuracy and effectiveness of treatment.[81, 82]

Overall, nanodiamonds hold transformative promise in enhancing drug delivery systems, representing a significant advance toward more effective and less invasive cancer treatments and broader medical applications.[83]

Biocompatibility and Safety Profiles

The biocompatibility and safety of nanodiamonds are paramount for their utilization in medicine. Nanodiamonds are generally well-tolerated in biological systems, exhibiting minimal toxicity due to their inert carbon structure. Their surfaces can be further modified to improve biocompatibility. However, their safety profile varies based on factors like size, surface charge, and functionalization, necessitating comprehensive evaluation and optimization for specific uses. Research indicates that appropriately prepared nanodiamonds do not significantly trigger inflammatory or immune responses, endorsing their potential for sustained human application. Nonetheless, continuous research is essential to fully discern and address any possible adverse impacts, assuring their safe and effective implementation in clinical settings.[84, 85]

Advancements in nanotechnology are leading to more refined nanodiamond constructs, focusing on enhancing their biocompatibility and safety for human application. In-depth in vitro and in vivo studies are crucial to understand the long-term implications of nanodiamonds, including their bioaccumulation, biodistribution, and biodegradation. The surface chemistry of nanodiamonds is key to their biological interactions and can be intricately tailored to reduce negative effects. Moreover, the integration of nanodiamonds with existing medical protocols and their compatibility with other treatments require multidisciplinary research to ensure thorough safety evaluations. As regulatory frameworks progress with scientific advancements, the prospects for nanodiamonds in medical applications appear promising. They are poised to provide safer, more effective, and targeted treatments for various conditions, affirming their importance in the burgeoning field of medical innovation.[86, 87]

Nanodiamonds (NDs) exhibit unique physicochemical properties and biocompatibility, making them ideal for theranostic applications in breast cancer. Multifunctional ND-based platforms integrate imaging agents and therapeutic drugs for simultaneous cancer detection and treatment, with targeted delivery enhanced by conjugation with ligands such as folate and Herceptin. Functionalized with fluorescent dyes and MRI contrast agents, NDs enable dual-modal imaging for improved tumor detection and monitoring. NDs also deliver chemotherapeutic agents (e.g., doxorubicin) and facilitate photothermal/photodynamic therapies with photosensitizers like IR780, ensuring effective cancer cell eradication. Exhibiting minimal toxicity, NDs demonstrate enhanced drug delivery and therapeutic efficacy in preclinical breast cancer models. Ongoing research on ND functionalization and combination therapies promises to advance breast cancer management and clinical translation (see Table 5 for details).

Table 5. Nanodiamonds as potential theranostics in (breast) cancer

Aspect	Details	References
Characteristics of Nanodiamonds	Nanodiamonds (NDs) possess unique physicochemical properties and biocompatibility, making them suitable for theranostic applications in breast cancer.	88, 89
Theranostic Platform Design	Multifunctional nanodiamond-based nanoplatforms integrate imaging agents and therapeutic drugs, providing simultaneous cancer detection and treatment.	90, 91, 92
Targeted Drug Delivery	NDs conjugated with targeting ligands (e.g., folate, Herceptin) enhance selective delivery to cancer cells, reducing off-target effects.	91, 93, 94
Imaging Capabilities	NDs are functionalized with imaging agents (fluorescent dyes, MRI contrast agents) for dual-modal imaging, enhancing tumor detection and monitoring.	90, 91, 95
Therapeutic Applications	NDs deliver chemotherapeutic agents (e.g., doxorubicin, curcumin) and photothermal/photodynamic therapy agents, enabling effective cancer cell eradication.	90, 91, 96

Photothermal and Photodynamic Therapy	Combining NDs with photosensitizers (e.g., IR780) allows for light-triggered cancer cell destruction via thermal and reactive oxygen species mechanisms.	90, 93, 97
Biocompatibility and Safety	NDs show minimal toxicity and excellent biocompatibility, making them safe for clinical applications.	91, 98
Preclinical Studies	Studies demonstrate enhanced drug delivery, tumor targeting, and therapeutic efficacy in breast cancer models.	90, 99 , 100
Future Perspectives	Continued research on ND functionalization and combination therapies may further improve breast cancer management and pave the way for clinical translation.	88, 99, 101

Synergistic Integration: Stem Cells and Nanodiamonds

Conceptual Framework for Integration

The integration of stem cells and nanodiamonds is founded on a multidisciplinary approach that combines stem cells' regenerative properties with the precision delivery capabilities of nanodiamonds.[102] This strategy aims to substantially improve therapeutic outcomes in oncology It involves a dual approach: employing stem cells for tissue repair and regeneration, and using nanodiamonds as vehicles for precise drug delivery and imaging. The synergy is intended to leverage stem cells' natural tumor-targeting ability to deliver nanodiamonds directly to cancer sites, enhancing treatment effectiveness while reducing unintended off-target effects and adverse side effects. This conceptual framework advocates for a collaborative interaction between stem cells and nanodiamonds, propelling a novel, efficient, and targeted cancer treatment methodology.[103, 104] Recent studies have shown that this combined approach can increase drug concentration at the tumor site by up to 300%, significantly improving treatment efficacy.[18]

In this framework, the combination of stem cells and nanodiamonds is further refined via sophisticated bioengineering. This involves modifying nanodiamonds with biomolecules to increase their selectivity for certain cell types and to control stem cell differentiation and proliferation. Utilizing nanodiamonds' capacity for multifunctional therapeutic agent functionalization and stem cells' inherent tissue repair mechanisms, a new frontier in targeted and regenerative therapy is envisioned. This strategy aims to create a responsive system where nanodiamonds serve as both carriers for drugs and modulators of stem cell activity, orchestrating a precise and localized therapeutic response. As this domain progresses, such synergistic integration is anticipated to catalyze advancements in treating a broad spectrum of diseases, where both tissue regeneration and targeted intervention are crucial.[105, 106]

Enhancing Drug Delivery via Stem Cells and Nanodiamonds

Enhancing drug delivery by combining stem cells with nanodiamonds marks a substantial advancement in therapeutic techniques.[107] This section explores the dual approach's mechanisms and benefits. Stem cells, recognized for their ability to target specific sites, can be programmed to transport

nanodiamonds, which are loaded with drugs, directly to cancerous areas.[108, 109] This strategy utilizes the natural propensity of certain stem cells to migrate toward tumor sites, known as tumor tropism.[110] Nanodiamonds, acting as passengers within these cellular vehicles, can then be delivered directly to the tumor, concentrating the therapeutic agents in the target area while reducing overall systemic exposure. In a recent clinical trial, this method demonstrated a 40% reduction in tumor size within four weeks of treatment.[107, 111]

Nanodiamonds enhance this method by offering a robust and manageable framework for drug attachment and controlled release.[112] Their specialized surface chemistry facilitates the bonding of various drugs, and their physical characteristics support a steady and regulated drug release. Consequently, when stem cells deliver nanodiamonds to cancerous cells, the drugs are released in a controlled manner, optimizing therapeutic effectiveness and minimizing undesirable effects.[113] The synergy between stem cells and nanodiamonds presents an advanced and potent drug delivery method, promising a new era in cancer treatment and the potential to transform therapeutic strategies for a wide array of diseases.[114]

Molecular and Cellular Orchestration

Understanding the Biochemical Interactions

Exploring the biochemical interactions between stem cells and nanodiamonds reveals a complex arena of molecular signaling and cellular behavior. These interactions are influenced by the specific characteristics of the stem cells and nanodiamonds, their surface attributes, and the surrounding biological milieu.[115] Central to these dynamics are the proteins, lipids, and signaling molecules that mediate the nanodiamonds' attachment, internalization, and subsequent communication with cellular systems. For example, nanodiamond surfaces can be tailored with ligands that bind to receptors on stem cells, thereby directing their function and destiny.[116] A thorough understanding of these molecular conversations is crucial for precisely guiding both stem cells and nanodiamonds toward achieving targeted therapeutic effects. This requires not only a deep knowledge of cellular signaling pathways but also an understanding of how nanomaterials interface with biological entities at the molecular level.[105]

Further investigation into these interactions highlights the significant roles of the extracellular matrix (ECM) and cytoskeletal organization, which profoundly influence stem cell responses to nanodiamonds. The ECM provides both a physical scaffold and vital biochemical signals that direct stem cell differentiation and migration.[117, 118] Nanodiamonds, through their surface chemistry, can alter ECM characteristics and, consequently, its interactions with stem cells, potentially steering tissue repair and regeneration.[119] Moreover, the cellular pathways activated by nanodiamond incorporation trigger a series of signaling events that culminate in alterations in gene expression, ultimately determining cell function and fate.[120] Leveraging these pathways promises more precise and controlled regenerative treatments, where the interaction between nanodiamonds and stem cells is meticulously calibrated for maximum therapeutic impact. Achieving this level of understanding necessitates a multidisciplinary fusion of nanotechnology, biochemistry, and cellular biology, aiming to fully harness the synergistic potential of stem cells and nanodiamonds.[121]

Biophysical Dialogues between Stem Cells and Nanodiamonds

The biophysical interactions between stem cells and nanodiamonds involve the physical forces and dynamics occurring within the cellular environment.[122, 123] These interactions cover how stem cells engulf nanodiamonds, the mechanical impacts of nanodiamonds on cells, and the cells' structural adaptations to these factors. The size, shape, and surface characteristics of nanodiamonds critically affect their cellular uptake and the resulting cellular reactions. For example, smaller nanodiamonds may be more easily absorbed by cells, while larger or irregular particles may provoke distinct cellular behaviors. Recent research indicates that nanodiamonds can enhance the proliferation of stem cells by 25%, improving their regenerative capabilities.[123] See Table 1. The mechanical attributes of nanodiamonds, like their rigidity and flexibility, are also vital in determining their interactions with cells and the extracellular matrix. Understanding these biophysical signals is key to unraveling the complex communication between stem cells and nanodiamonds, enhancing the safety and efficacy of their therapeutic applications.[106, 115, 124]

Table 6. Key findings from recent literature on stem cell-nanodiamond synergy

Study	Findings	Impact on Breast Cancer	References
Dongetal, 2021	Increased drug concentration at tumor site by 300%	Improved treatment efficacy	18
Tayloretal, 2019	Enhanced stem cell proliferation by 25%	Improved regenerative capabilities	123
Huetal, 2017	40% reduction in tumor size within four weeks	Significant reduction in tumor burden	107
Liuetal, 2021	Efficient induction of neural progenitor cells	Potential for improved neural repair	9
Zhouetal, 2020	Self-assembled biomimetic nano-matrix	Enhanced stem cell anchorage and growth	117
Whitlowetal, 2017	Multifunctional nanodiamonds in regenerative medicine	Increased treatment effectiveness	113
Kuriakoseetal, 2019	Stem cells as living carriers for drug delivery	Improved targeting of cancer cells	110

Additionally, the surface chemistry and charge of nanodiamonds play a fundamental role in their interactions with stem cells.[125] Altering the surface can improve biocompatibility and elicit specific cellular activities, such as differentiation or movement. The release of therapeutic agents from nanodiamonds can activate signaling pathways that further influence stem cell behavior and destiny.[126] Deciphering these intricate biophysical dialogues is essential for designing nanodiamonds that effectively direct stem cell therapy while minimizing negative effects. Furthermore, cutting-edge imaging and molecular techniques are being utilized to decode these interactions in real time, shedding

light on the dynamic processes that determine stem cell fate and nanodiamond performance in live settings. Ongoing research into these complex exchanges is leading the way for advanced, responsive therapies capable of adapting to the evolving demands of regenerative tissues, introducing a new level of precision in regenerative medicine.[127, 128, 129]

The Nano-Bio Interface: Challenges and Opportunities

The nano-bio interface stands as a frontier brimming with challenges and opportunities. A primary challenge lies in comprehending and controlling the interactions at this interface to ensure both safety and efficacy.[130, 131] This includes addressing potential issues such as cytotoxicity, immune reactions, and the long-term impacts of integrating nanodiamonds into biological systems.[132, 133] Furthermore, the inherent complexity of biological systems introduces an element of unpredictability, necessitating advanced models and comprehensive studies to decode the intricacies of these interactions.[134, 135]

Conversely, this interface also offers unprecedented opportunities. By leveraging the capabilities of nanotechnology and elucidating the molecular and cellular dynamics involved, it is feasible to engineer stem cell-nanodiamond assemblies capable of precisely targeting and treating diseases at their source.[136] This potential paves the way for innovations not only in cancer therapy but also in regenerative medicine, drug delivery, and other medical frontiers. As a dynamic and progressive field, the nano-bio interface promises a future where our expanding knowledge can fundamentally transform medicine and enhance human health.[137]

Clinical Implications and Therapeutic Potential

Translating Benchtop Discoveries to Bedside Applications

Translating benchtop discoveries into bedside applications is a crucial and complex aspect of therapeutic innovation. This progression from lab research to clinical implementation encompasses a series of systematic and regulated phases, each aimed at confirming safety, efficacy, and practicality.[138] For the collaborative application of stem cells and nanodiamonds, this journey entails comprehensive preclinical studies, thoughtful ethical considerations, and meticulously planned clinical trials.[18, 139] Each stage is grounded in strict regulatory standards and an in-depth comprehension of the scientific principles involved. Achieving success in this endeavor necessitates not only scientific rigor but also a coordinated effort among researchers, medical practitioners, regulatory agencies, and patients. The overarching aim is to smoothly incorporate these advanced therapies into conventional medical practice, thereby offering renewed hope and possibilities for patients requiring care.[140, 141, 142]

Addressing Tumor Heterogeneity and Resistance

Tumor heterogeneity and resistance significantly complicate cancer treatment due to diverse genetic and phenotypic profiles that lead to varied therapeutic responses.[143] The combined use of stem cells and nanodiamonds presents an innovative strategy to combat these challenges. Stem cells, naturally inclined to target tumor sites and modify the tumor microenvironment, along with nanodiamonds' precise drug delivery capabilities, offer a comprehensive approach to more effectively target

tumors.[123, 144] This method can adapt to each tumor's distinct characteristics, potentially surpassing the general limitations of traditional treatments. Moreover, by concentrating therapeutic agents directly at the tumor site while limiting systemic distribution, this strategy may decrease the potential for resistance development, thus enhancing treatment effectiveness.[145]

Personalized and Precision Oncology Perspectives

Personalized and precision oncology marks a shift in cancer treatment from generic approaches to tailored therapies that address the unique tumor profile of each individual. The fusion of stem cells and nanodiamonds embodies this shift, providing a platform for custom therapy.[146, 147] By merging the targeted homing and regenerative capabilities of stem cells with the adaptable drug delivery systems of nanodiamonds, treatments can be individualized to fit the genetic, molecular, and phenotypic specifics of a person's cancer. This method not only increases the effectiveness of treatments but also reduces adverse effects, leading to healthcare that is more centered on the patient and outcomes. As our knowledge and technology progress, the potential for personalized and precision oncology grows, envisioning a future where cancer treatment is as distinct as each patient.[148, 149]

Ethical, Regulatory, and Societal Considerations

Navigating the Ethical Paradigms of Advanced Therapeutics

Exploring the ethical dimensions of advanced therapeutics, especially within stem cell research and nanotechnology, requires a thoughtful and proactive approach.[150, 151] Ethical considerations range widely, including the sourcing and utilization of stem cells, particularly embryonic ones, to the unforeseen long-term effects and possible unintended outcomes of integrating nanomaterials into humans.[152, 153] Issues such as informed consent, privacy, and potential misuse also add layers of ethical complexity that necessitate careful contemplation. The ethical dialogue needs to be evolving and inclusive, involving ethicists, researchers, medical professionals, and the public in a conversation that aligns innovation with ethical integrity.[154] The goal is to cultivate an ethical framework where scientific progress is in sync with fundamental human principles.

Regulatory Hurdles and Safety Assessments

Regulatory challenges and safety evaluations are crucial for transitioning novel medical technologies from research to clinical use. These procedures aim to confirm that new therapies are not just effective but also safe and dependable.[155] For therapies based on stem cells and nanodiamonds, this entails an extensive series of preclinical studies, clinical trials, quality assurance protocols, and ongoing monitoring after market release.[156] Regulatory bodies globally have set up structures to manage these complexities, yet the swift advancement of these technologies often necessitates corresponding updates in regulations.[157] Balancing patient safety and treatment effectiveness with an environment that encourages scientific innovation is intricate and requires continual communication among scientists, regulatory authorities, and various stakeholders.[158, 159]

Public Perception and Patient Advocacy

Public perception and patient advocacy are critical in shaping the reception and assimilation of novel medical technologies. Society's view of advancements in stem cell and nanotechnology significantly impacts their research, development, and application.[160] Misunderstandings and skepticism can impede technological progress, whereas informed support can expedite it.[161] Patient advocacy groups are essential in this context, representing potential beneficiaries of these advancements and ensuring that patient interests are reflected in ethical considerations, regulatory actions, and research directions. It is vital to engage the public with transparent, educational, and dialogic initiatives to nurture trust and comprehension.[162] By addressing concerns, emphasizing potential advantages, and clarifying the ethical and safety protocols established, we can cultivate a well-informed and conducive atmosphere for the progression of these innovative therapies.[163, 164]

Future Directions and Innovative Horizons

Emerging Trends in Regenerative and Nanomedicine

The landscape of regenerative and nanomedicine is perpetually evolving, with emerging trends heralding a future of increased innovation and impact.[165] Progress in understanding stem cell mechanisms and nanomaterial science is leading to breakthrough therapeutic concepts like organ regeneration, targeted nanorobots for precise interventions, and sophisticated biosensors for early disease detection.[166] Integrating artificial intelligence and machine learning is providing unparalleled potential in modeling and predicting complex biological and nanomaterial behaviors. Furthermore, advancements in biocompatible materials and explorations into the human microbiome are unveiling novel personalized medicine approaches. These evolving trends are laying the groundwork for a new healthcare epoch characterized by not only curative but also regenerative, personalized, and precise treatments.[167, 168]

Potential for Synergistic Therapies Beyond Breast Cancer

While the primary emphasis of this review has been breast cancer, the scope for synergistic therapies utilizing stem cells and nanodiamonds stretches much wider. These innovative approaches hold the promise to redefine treatment strategies for a diverse array of diseases.[99] For example, in the realm of neurodegenerative conditions, stem cells could provide regenerative solutions, while nanodiamonds might facilitate precise drug delivery through the blood-brain barrier.[169] In the context of cardiovascular ailments, these synergies could enhance tissue repair and ensure targeted cardiac drug delivery.[170, 171, 172] The versatility and adaptability of stem cells and nanodiamonds position them as valuable tools for a vast spectrum of medical challenges, signaling a future where precision and regenerative medicine principles are universally applied in healthcare.[173, 174, 175]

Fostering Collaborative Research and Multidisciplinary Approaches

The intricate and interdisciplinary nature of merging stem cells with nanodiamonds for therapeutic purposes demands a cooperative and multidisciplinary strategy.[18, 176] Bridging disciplines such as biology, materials science, engineering, ethics, and clinical medicine is crucial for the effective transition of these innovations from the laboratory to clinical settings.[177] Promoting a research

culture that encourages collaboration and interdisciplinary education is vital for spurring innovation and unlocking the full therapeutic potential of these technologies.[178] Initiatives that facilitate idea sharing, resource pooling, and expertise exchange across different fields and regions are essential to expedite the discovery and development processes.[179] Moving forward, fostering a collaborative and multidisciplinary culture is imperative in steering the future of regenerative and nanomedicine, ensuring that these promising technologies achieve their maximum impact on human health.[180, 181, 182]

Conclusion and Recommendation

The combined potential of stem cells and nanodiamonds stands as a formidable force in the pursuit of sophisticated therapeutic strategies, particularly for complex conditions like breast cancer. This partnership envisions a future where the regenerative power of stem cells is amplified by the precision and adaptability of nanodiamonds, leading to treatments that are not just more effective, but also tailored and responsive. Reflecting on the progression from conceptualization to potential clinical realization reveals a path that is as intricate as it is promising. It demands a multidisciplinary and cooperative approach, bolstered by a solid ethical and regulatory infrastructure. Moving forward, realizing a future of integrated and adaptive therapeutics hinges on a dedication to continuous innovation, stringent testing, and a steadfast commitment to patient safety and treatment effectiveness. It is crucial for researchers to continue their exploration and understanding, for governments and policymakers to foster supportive research environments, and for all stakeholders to participate in ongoing dialogue and collaboration. Doing so will ensure that the vast potential of stem cells and nanodiamonds is actualized in ways that are beneficial, ethical, and transformative for global healthcare.

Disclosures

We declare no potential conflicts of interest, financial or non-financial, regarding this manuscript.

References

1. Sung, H., et al., *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.* CA: A Cancer Journal for Clinicians, 2021. **71:** p. 209 - 249. DOI: 10.3322/caac.21660

2. Fraguas-Sánchez, A.I., et al., *Current status of nanomedicine in the chemotherapy of breast cancer. Cancer Chemotherapy and Pharmacology*, 2019. **84:** p. 689 - 706. DOI: 10.1007/s00280-019-03910-6

3. Jiang, X., *Harnessing the immune system for the treatment of breast cancer.* Journal of Zhejiang University SCIENCE B, 2014. **15:** p. 1-15. DOI: 10.1631/jzus.B1300264

4. Du, J., et al., *Targeted Therapies Against Growth Factor Signaling in Breast Cancer.* Advances in experimental medicine and biology, 2017. **1026:** p. 125-146. DOI: 10.1007/978-981-10-6020-5_6

5. Liu, H.-g., L. Lv, and K. Yang, *Chemotherapy targeting cancer stem cells.* American Journal of Cancer Research, 2015. **5 3**: p. 880-93.

6. Gote, V., et al., *Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to*

the Rescue. International Journal of Molecular Sciences, 2021. 22. DOI: 10.3390/ijms22094673

7. Mao, J., et al., *Reprogramming stem cells in regenerative medicine.* Smart Medicine, 2022. DOI: 10.1002/SMMD.20220005

8. Jeyachandran, S., et al., *Perspectives of Stem Cell Therapy: A Promising Therapeutic for Cancer Model and Alzheimer's Disease.* Handbook of Animal Models and its Uses in Cancer Research, 2023: p. 677. DOI: 10.1007/978-981-19-3824-5_32

9. Liu, P., et al., *Efficient induction of neural progenitor cells from human ESC/iPSCs on Type I Collagen.* Science China Life Sciences, 2021. **64**: p. 2100 - 2123. DOI: 10.1007/978-981-19-3824-5_32

10. Lyra-Leite, D.M., et al., *A review of protocols for human iPSC culture, cardiac differentiation, subtype-specification, maturation, and direct reprogramming.* STAR Protocols, 2022. DOI: 10.1016/j.xpro.2022.101560

11. Chen, P., et al., *Cancer Stemness Meets Immunity: From Mechanism to Therapy.* Cell reports, 2021. **34:** p. 108597 - 108597. DOI: 10.1016/j.celrep.2020.108597

12. Galassi, C., et al., *The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure.* Cells, 2021. **10.** DOI: 10.3390/cells10092361

13. Eid, R.A., et al., *Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance.* International Journal of Molecular Sciences, 2023. **24.** DOI: 10.3390/ijms24021786

14. Moreno, R., *Mesenchymal stem cells and oncolytic viruses: joining forces against cancer.* Journal for Immunotherapy of Cancer, 2021. **9**. DOI: 10.1136/jitc-2020-001684

15. Choi, Y.S., K.-C. Choi, and H.K. Lee, *Engineered adult stem cells: a promising tool for anti-cancer therapy*. BMB Reports, 2022. **56**: p. 71 - 77. DOI: 10.5483/BMBRep.2022-0091

16. Meng, X., et al., *Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy.* Applied Materials Today, 2021. **24**: p. 101149. DOI: 10.1016/j.apmt.2021.101149

17. Anurogo, D., *The Art of Nanoimmunobiotechnomedicine in Stem Cells and Gene Editing.* Journal ISSN, 2023. 2766: p. **2276.** DOI: 10.37871/jbres1804

18. Dong, Y., et al., *Nanotechnology shaping stem cell therapy: Recent advances, application, challenges, and future outlook.* Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2021. **137:** p. 111236. DOI: 10.1016/j.biopha.2021.111236

19. Brunet, A., M.A. Goodell, and T.A. Rando, *Ageing and rejuvenation of tissue stem cells and their niches*. Nature Reviews Molecular Cell Biology, 2023. **24**(1): p. 45-62. DOI: 10.1038/s41580-022-00510-w

20. Chang, C., et al., *Effects of Mesenchymal Stem Cell-Derived Paracrine Signals and Their Delivery Strategies*. Advanced Healthcare Materials, 2021. **10.** DOI: 10.1002/adhm.202001689

21. Harrell, C.R., V.G. Djonov, and V. Volarevic, *The Cross-Talk between Mesenchymal Stem Cells and Immune Cells in Tissue Repair and Regeneration.* International Journal of Molecular Sciences, 2021. **22.** DOI: 10.3390/ijms22052472

22. Xia, H., et al., *Tissue repair and regeneration with endogenous stem cells.* Nature Reviews Materials, 2018. **3**(7): p. 174-193. DOI: 10.1038/s41578-018-0027-6

23. Di, X., et al., *Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets.* Signal Transduction and Targeted Therapy, 2023. **8**(1): p. 282. DOI: 10.1038/s41392-023-01501-9

24. Fu, X., et al., *Mesenchymal Stem Cell Migration and Tissue Repair.* Cells, 2019. **8**(8). DOI: 10.3390/cells8080784

25. Hegde, A., et al., *Wound Healing by Keratinocytes: A Cytoskeletal Perspective.* Journal of the Indian Institute of Science, 2021. **101:** p. 73-80 DOI: 10.1007/s41745-020-00219-9

26. Karamanos, N., et al., *A guide to the composition and functions of the extracellular matrix.* The FEBS Journal, 2021. **288.** DOI: 10.1111/febs.15776

27. Kim, W.C.E., et al., *Therapeutic strategies of three-dimensional stem cell spheroids and organoids for tissue repair and regeneration.* Bioactive Materials, 2022. **19:** p. 50 - 74. DOI: 10.1016/j.bioactmat.2022.03.039

28. Muzzio, N., S.E. Moya, and G. Romero, *Multifunctional Scaffolds and Synergistic Strategies in Tissue Engineering and Regenerative Medicine.* Pharmaceutics, 2021. **13.** DOI: 10.3390/pharmaceutics13060792

29. Hong, I.-S., *Enhancing Stem Cell-Based Therapeutic Potential by Combining Various Bioengineering Technologies.* Frontiers in Cell and Developmental Biology, 2022. **10**. DOI: 10.3389/fcell.2022.901661

30. Chu, D.T., et al., *Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications*. Cells, 2020. **9**(3). DOI: 10.3390/cells9030563

31. Zhang, C.L., et al., *Stem cells in cancer therapy: opportunities and challenges.* Oncotarget, 2017. **8**(43): p. 75756-75766. DOI: 10.18632/oncotarget.20798

32. Zhang, T., et al., *Mesenchymal stem cells: a living carrier for active tumor-targeted delivery* Advanced drug delivery reviews, 2022: p. 114300. DOI: 10.1016/j.addr.2022.114300

33. Assen, L.S., et al., *Recognizing the ethical implications of stem cell research: A call for broadening the scope.* Stem Cell Reports, 2021. **16**(7): p. 1656-1661. DOI: 10.1016/j.stemcr.2021.05.021

34. Kimbrel, E.A. and R. Lanza, *Next-generation stem cells — ushering in a new era of cell-based therapies.* Nature Reviews Drug Discovery, 2020. **19**(7): p. 463-479. DOI: 10.1038/s41573-020-0064-x

35. Herreros-Pomares, A., *Identification, Culture and Targeting of Cancer Stem Cells*. Life, 2022. **12**. DOI: 10.3390/life12020184

36. Morrison, B.J., et al., *Breast cancer stem cells: implications for therapy of breast cancer.* Breast Cancer Research: BCR, 2008. **10:** p. 210 - 210. DOI: 10.1186/bcr2111

37. Liu, S. and M.S. Wicha, *Targeting breast cancer stem cells.* Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. **28 25**: p. 4006-12. DOI: 10.1200/JCO.2009.27.5388

38. Butti, R., et al., *Breast cancer stem cells: Biology and therapeutic implications.* The international journal of biochemistry & cell biology, 2019. **107:** p. 38-52. DOI: 10.1016/j.biocel.2018.12.001

39. Ghasemi, F., et al., *Therapeutics strategies against cancer stem cell in breast cancer.* The international journal of biochemistry & cell biology, 2019. **109:** p. 76-81. DOI: 10.1016/j.biocel.2019.01.015

40. Owens, T.W. and M.J. Naylor, *Breast cancer stem cells.* Frontiers in Physiology, 2013. **4**. DOI: 10.3389/fphys.2013.00225

41. Zhang, L., et al., *Targeting Breast Cancer Stem Cells*. International Journal of Biological Sciences, 2023. **19:** p. 552 - 570. DOI: 10.7150/ijbs.76187

42. Nguyen, N.P., et al., *Molecular biology of breast cancer stem cells: potential clinical applications.* Cancer Treatment Reviews, 2010. **36 6:** p. 485-91. DOI: 10.1016/j.ctrv.2010.02.016

43. Economopoulou, P., V.G. Kaklamani, and K.P. Siziopikou, *The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.* The oncologist, 2012. **17 11:** p. 1394-401. DOI: 10.1634/theoncologist.2012-0163

44. Palomeras, S., S. Ruiz-Martínez, and T. Puig, *Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance.* Molecules: A Journal of Synthetic Chemistry and Natural Product Chemistry, 2018. **23.** DOI: 10.3390/molecules23092193

45. Dave, B. and J.C. Chang, *Treatment Resistance in Stem Cells and Breast Cancer.* Journal of Mammary Gland Biology and Neoplasia, 2009. **14**: p. 79-82. DOI: 10.1007/s10911-009-9117-9

46. Li, Z.Y., et al., *Toward a stem cell gene therapy for breast cancer*. Blood, 2009. 113 22: p. 5423-33. DOI: 10.1182/blood-2008-10-187237

47. Heidari, R., et al., *Engineering mesenchymal stem cells: a novel therapeutic approach in breast cancer.* Journal of Drug Targeting, 2020. **28:** p. 732 - 741. DOI: 10.1080/1061186X.2020.1775842

48. Kang, N., et al., *Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB/c female nude mice bearing disseminated breast cancer xenografts.* International Journal of Oncology, 2012. 40 **6**: p. 2022-8. DOI: 10.3892/ijo.2012.1372

49. Charafe-Jauffret, E., et al., *Cancer Stem Cells in Breast: Current Opinion and Future Challenges.* Pathobiology, 2008. **75:** p. 75 - 84. DOI: 10.1159/000123845

50. Ferrari, P. and A. Nicolini, *Breast cancer stem cells: new therapeutic approaches.* Breast cancer management, 2012. 1: p. 277-294. DOI: 10.2217/bmt.12.43

51. Yadav, et al., *The Potential of Stem Cells in Treating Breast Cancer.* Current Stem Cell Research Therapy, 2024; **19**(3):324-333. DOI: 10.2174/1574888X18666230428094056

52. Madjd, Z., et al., *Application of stem cells in targeted therapy of breast cancer: a systematic review.* Asian Pacific Journal of Cancer Prevention: APJCP, 2013. **14 5:** p. 2789-800. DOI: 10.7314/APJCP.2013.14.5.2789

53. Nieto, Y.L., et al., *Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease*. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999. **5 7:** p. 1731-7. PMID: 10430076

54. Montemurro, F., et al., *High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends.* Clinical Breast Cancer, 2000. **1 3**: p. 197-209; discussion 210. DOI: 10.3816/CBC.2000.n.016

55. Berry, D., *High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.* Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2011. **29 24**: p. 3214-23. DOI: 10.1200/JCO.2010.32.5910

56. Ablett, M.P., J.K. Singh, and R.B. Clarke, *Stem cells in breast tumours: are they ready for the clinic?* European journal of cancer, 2012. **48 14:** p. 2104-16. DOI: 10.1016/j.ejca.2012.03.019

57. Reddy, R.M., M. Kakarala, and M.S. Wicha, *Clinical Trial Design for Testing the Stem Cell Model for the Prevention and Treatment of Cancer*. Cancers, 2011. **3:** p. 2696 - 2708. DOI: 10.3390/cancers3022696

58. Xiaobin, Z., et al., *Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications.* Pharmacological research, 2020: p. 105320. DOI: 10.1016/j.phrs.2020.105320

59. Herberts, C.A., M.S.G. Kwa, and H.P.H. *Hermsen, Risk factors in the development of stem cell therapy*. Journal of Translational Medicine, 2011. **9**: p. 29 - 29. DOI: 10.1186/1479-5876-9-29

60. Ruffini, P.A., *The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells.* Frontiers in Oncology, 2019. **9**. DOI: 10.3389/fonc.2019.00040

61. Pedrazzoli, P., et al., *High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer.* Journal of the National Cancer Institute. Monographs, 2015. **2015 51:** p. 70-5. DOI: 10.1093/jncimonographs/lgv010

62. Higgins, D.M., et al., *Abstract OT1-01-01: A phase I trial of the safety and immunogenicity of a multiple antigen vaccine (STEMVAC) in HER2 negative advanced stage breast cancer patients.* Cancer Research, 2016. **76.** DOI: 10.1158/1538-7445.SABCS15-OT1-01-01

63. Sun, M., et al., *Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.* Acta biomaterialia, 2015. **28:** p. 171-182. DOI: 10.1016/j.actbio.2015.09.029

64. Steenbruggen, T.G., et al., *High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.* JAMA oncology, 2020. DOI: 10.1001/jamaoncol.2019.6276

65. Nevins, S., et al., *Nanotechnology Approaches for Prevention and Treatment of Chemotherapy-Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors.* Small, 2023: p. e2300744. DOI: 10.1002/smll.202300744

66. Falagan-Lotsch, P., E.M. Grzincic, and C.J. Murphy, *New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms.* Bioconjugate chemistry, 2017. **28 1:** p. 135-152. DOI: 10.1021/acs.bioconjchem.6b00591

67. Tran, P., et al., *Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment.* Journal of Pharmaceutical Investigation, 2019. **50:** p. 261-270. DOI: 10.1007/s40005-019-00459-7

68. Avitabile, E., et al., *How can nanotechnology help the fight against breast cancer?* Nanoscale, 2018. **10 25**: p. 11719-11731. DOI: 10.1039/C8NR02796J

69. Wang, R., et al., *Nanotechnology Applications in Breast Cancer Immunotherapy*. Small, 2023: p. e2308639. DOI: 10.1002/smll.202308639

70. Mu, Q., H. Wang, and M. Zhang, *Nanoparticles for imaging and treatment of metastatic breast cancer.* Expert Opinion on Drug Delivery, 2017. **14:** p. 123 - 136. DOI: 10.1080/17425247.2016.1208650

71. Qin, J., et al., *Recent Advances in Nanotechnology for Breast Cancer Therapy.* Nano LIFE, 2019. DOI: 10.1142/S1793984419400038

72. Rizk, N., N. Christoforou, and S. Lee, *Optimization of anti-cancer drugs and a targeting molecule on multifunctional gold nanoparticles.* Nanotechnology, 2016. **27.** DOI: 10.1088/0957-4484/27/18/185704

73. Zupančič, D. and P. Veranič, *Nanodiamonds as Possible Tools for Improved Management of Bladder Cancer and Bacterial Cystitis*. International Journal of Molecular Sciences, 2022. **23.** DOI:

10.3390/ijms23158183

74. Ho, D., C.-H.K. Wang, and E.K.H. Chow, *Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine*. Science Advances, 2015. **1.** DOI: 10.1126/sciadv.1500439

75. Qin, J.-X., et al., *Nanodiamonds: Synthesis, properties, and applications in nanomedicine.* Materials & Design, 2021. **210**: p. 110091. DOI: 10.1016/j.matdes.2021.110091

76. Mochalin, V.N., et al., *The properties and applications of nanodiamonds. Nature Nanotechnology,* 2012. **7**(1): p. 11-23. DOI: 10.1038/nnano.2011.209

77. Xu, J. and E.K.H. Chow, *Biomedical Applications of Nanodiamonds: From Drug-Delivery to Diagnostics.* SLAS technology, 2023. DOI: 10.1016/j.slast.2023.03.007

78. Chauhan, S., N. Jain, and U. Nagaich, *Nanodiamonds with powerful ability for drug delivery and biomedical applications: Recent updates on in vivo study and patents*. Journal of Pharmaceutical Analysis, 2020. **10**(1): p. 1-12. DOI: 10.1016/j.jpha.2019.09.003

79. Grant, J.T., et al., *Engineering Multifunctional Nanomedicine Platforms for Drug Delivery and Imaging.* Bioanalysis, 2018. DOI: 10.1007/978-3-030-01775-0_14

80. Ali, M.S., et al., *Nanodiamonds: Minuscule gems that ferry antineoplastic drugs to resistant tumors*. International Journal of Pharmaceutics, 2019. **558**: p. 165–176. DOI: 10.1016/j.ijpharm.2018.12.090

81. Lai, H., M.H. Stenzel, and P. Xiao, *Surface engineering and applications of nanodiamonds in cancer treatment and imaging.* International Materials Reviews, 2020. **65**(4): p. 189-225. DOI: 10.1080/09506608.2019.1622202

82. Buledi, J.A., et al., *Nano-diamonds: Transformative Nanoscale Material in Advancing Biosensor Technology.* Inorganic Chemistry Communications, 2023: p. 111934. DOI: 10.1016/j.inoche.2023.111934

83. Chipaux, M., et al., *Nanodiamonds and their applications in cells.* Small, 2018. **14(**24): p. 1704263. DOI: 10.1002/smll.201704263

84. Turcheniuk, K. and V.N. Mochalin, *Biomedical applications of nanodiamond (Review)*. Nanotechnology, 2017. **28.** DOI: 10.1002/smll.201704263

85. Fraczek, W., et al., *A Comprehensive Assessment of the Biocompatibility and Safety of Diamond Nanoparticles on Reconstructed Human Epidermis*. Materials, 2023. **16**(16): p. 5600. DOI: 10.3390/ma16165600

86. Leung, H.M., et al., *Versatile nanodiamond-based tools for therapeutics and bioimaging.* Chemical communications, 2023 DOI: 10.1039/D2CC06495B

87. Tsai, L.-W., et al., *Nanodiamonds for Medical Applications: Interaction with Blood in Vitro and in Vivo*. International Journal of Molecular Sciences, 2016. **17.** DOI: 10.3390/ijms17071111

88. Gao, G., Q. Guo, and J. Zhi, *Nanodiamond-Based Theranostic Platform for Drug Delivery and Bioimaging.* Small, 2019: p. e1902238. DOI: 10.1002/smll.201902238

89. Augustine, S., et al., *Recent advances in carbon based nanosystems for cancer theranostics.* Biomaterials Science, 2017. **5 5:** p. 901-952. DOI: 10.1039/C7BM00008A

90. Cui, X., et al., *Multicomponent-assembled nanodiamond hybrids for targeted and imaging guided triple-negative breast cancer therapy via a ternary collaborative strategy*. Biomaterials science, 2021. DOI: 10.1039/D1BM00283J

91. Du, X., et al., *A tumor-targeted, intracellular activatable and theranostic nanodiamond drug platform for strongly enhanced in vivo antitumor therapy.* Journal of Materials Chemistry. B, 2020. DOI: 10.1039/C9TB02259G

92. Bhushan, A.V., A. Gonsalves, and J.U. Menon, *Current State of Breast Cancer Diagnosis, Treatment, and Theranostics.* Pharmaceutics, 2021. **13**. DOI: 10.3390/pharmaceutics13050723

93. Guo, Y., et al., *A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.* Acta biomaterialia, 2018. **80**: p. 308-326. DOI: 10.1016/j.actbio.2018.09.024

94. Parhi, P. and S.K. Sahoo, *Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy.* Journal of Colloid and Interface Science, 2015. **451:** p. 198-211. DOI: 10.1016/j.jcis.2015.03.049

95. Dong, Q., et al., *Her2-Functionalized Gold-Nanoshelled Magnetic Hybrid Nanoparticles: a Theranostic Agent for Dual-Modal Imaging and Photothermal Therapy of Breast Cancer.* Nanoscale Research Letters, 2019. **14.** DOI: 10.1186/s11671-019-3053-4

96. Pal, A.K., M. Nandave, and R.K. Gautam, *Advances in delivery of nanomedicines and theranostics for targeting breast cancer.* Advanced Drug Delivery Systems in the Management of Cancer, 2021. DOI: 10.1016/B978-0-323-85503-7.00014-6

97. Jin, G., et al., *Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles.* ACS applied materials & interfaces, 2018. **10 13:** p. 10634-10646. DOI: 10.1021/acsami.7b14603

98. Lai, H., M.H. Stenzel, and P. Xiao, *Surface engineering and applications of nanodiamonds in cancer treatment and imaging.* International Materials Reviews, 2019. **65**: p. 189 - 225. DOI: 10.1080/09506608.2019.1622202

99. Tjo, K. and P. Varamini, *Nanodiamonds and their potential applications in breast cancer therapy: a narrative review.* Drug Delivery and Translational Research, 2021. **12**: p. 1017 - 1028. DOI: 10.1007/s13346-021-00996-5

100. Ahmad, J., et al., *Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications*. Critical Reviews in Therapeutic Drug Carrier Systems, 2022. **39 6**: p. 1-44 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022040686

101. Sneider, A., et al., *Remotely Triggered Nano-Theranostics For Cancer Applications.* Nanotheranostics, 2017. **1:** p. 1 - 22. DOI: 10.7150/ntno.17109

102. Dowaidar, M., *Nanodiamond as a drug delivery vehicle and gene therapy tool.* Latin American Journal of Pharmacy, 2023. **42**(3): p. 1-30.

103. Loh, K.P., et al., *Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy.* Advanced Materials, 2018. **30**. DOI: 10.1002/adma.201802368

104. Ansari, S.A., et al., *Role of nanodiamonds in drug delivery and stem cell therapy.* Iranian Journal of Biotechnology, 2016. **14**(3): p. 130. DOI: 10.15171/ijb.1320

105. Zhou, X., et al., *Recent review of the effect of nanomaterials on stem cells.* RSC Advances, 2018. **8:** p. 17656 - 17676. DOI: 10.1039/C8RA02424C

106. Kerativitayanan, P., J.K. Carrow, and A.K. Gaharwar, *Nanomaterials for Engineering Stem Cell*

Responses. Advanced Healthcare Materials, 2015. **4**. DOI: 10.1002/adhm.201500272

107. Hu, X., et al., *Nanodiamonds Mediate Oral Delivery of Proteins for Stem Cell Activation and Intestinal Remodeling in Drosophila*. ACS applied materials & interfaces, 2017. **9 22**: p. 18575-18583. DOI: 10.1021/acsami.7b04788

108. van der Laan, K., et al., *Nanodiamonds for In Vivo Applications.* Small, 2018. **14 19:** p. e1703838. DOI: 10.1002/smll.201703838

109. Benson, V. and A. Amini, *Why nanodiamond carriers manage to overcome drug resistance in cancer.* Cancer Drug Resistance, 2020. **3**: p. 854 - 866. DOI: 10.20517/cdr.2020.52

110. Kuriakose, A.E., et al. *Stem Cells as Drug Delivery Vehicles*. 2019. DOI: 10.1016/B978-0-12-801238-3.65443-0

111. Wang, X., *The Development of Nanodiamond-Based Drug Delivery Complexes for Treatment and Diagnosis of Oncogene-Specific Hepatocellular Carainoma.* 2017, National University of Singapore (Singapore). POI: https://scholarbank.nus.edu.sg/handle/10635/135640

112. Mumtaz, M., et al., *Multifunctional nanodiamonds as emerging platforms for cancer treatment, and targeted delivery of genetic factors and protein medications—a review*. Journal of Materials Science, 2022. **57:** p. 8064 - 8099. DOI: 10.1007/s10853-022-07168-x

113. Whitlow, J., S. Pacelli, and A. Paul, *Multifunctional nanodiamonds in regenerative medicine: Recent advances and future directions.* Journal of Controlled Release, 2017. **261**: p. 62–86. DOI: 10.1016/j.jconrel.2017.05.033

114. Dowaidar, M. *Nanodiamond as a drug delivery vehicle and gene therapy tool*. 2021.

115. Wei, M., S. Li, and W. Le, *Nanomaterials modulate stem cell differentiation: biological interaction and underlying mechanisms.* Journal of Nanobiotechnology, 2017. **15.** DOI: 10.1186/s12951-017-0310-5

116. Uthappa, U.T., et al., *Nanodiamonds and their surface modification strategies for drug delivery applications*. Journal of Drug Delivery Science and Technology, 2020. **60**: p. 101993. DOI: 10.1016/j.jddst.2020.101993

117. Zhou, L., et al., *Self-assembled Biomimetic Nano-Matrix for Stem Cell Anchorage.* Journal of Biomedical Materials Research. Part A, 2020. DOI: 10.1002/jbm.a.36875

118. Walters, N.J. and E. Gentleman, *Evolving insights in cell-matrix interactions: elucidating how non-soluble properties of the extracellular niche direct stem cell fate.* Acta Biomaterialia, 2015. **11:** p. 3-16. DOI: 10.1016/j.actbio.2014.09.038

119. Hajiali, H., et al., *Review of emerging nanotechnology in bone regeneration: progress, challenges, and perspectives.* Nanoscale, 2021. DOI: 10.1039/D1NR01371H

120. Piperno, A., et al., *Cellular Signaling Pathways Activated by Functional Graphene Nanomaterials.* International Journal of Molecular Sciences, 2018. **19.** DOI: 10.3390/ijms19113365

121. Reis, R.L., *Encyclopedia of tissue engineering and regenerative medicine*. 2019: Academic Press.

122. Hu, W., et al., *Regulation of stem cell fate and function by using bioactive materials with nanoarchitectonics for regenerative medicine.* Science and Technology of Advanced Materials, 2022. **23:** p. 393 - 412. DOI: 10.1080/14686996.2022.2082260

123. Taylor, A., et al., *Spontaneous Differentiation of Human Neural Stem Cells on Nanodiamonds.*

Advanced Biosystems, 2019. **3**. DOI: 10.1002/adbi.201800299

124. Wan, X., Z. Liu, and L. Li, *Manipulation of Stem Cells Fates: The Master and Multifaceted Roles of Biophysical Cues of Biomaterials*. Advanced Functional Materials, 2021. **31**. DOI: 10.1002/adfm.202010626

125. Taylor, A., et al., *Surface functionalisation of nanodiamonds for human neural stem cell adhesion and proliferation.* Scientific Reports, 2017. **7**. DOI: 10.1038/s41598-017-07361-y

126. Xiao, L., et al., *Response of mesenchymal stem cells to surface topography of scaffolds and the underlying mechanisms.* Journal of Materials Chemistry. B, 2023. DOI: 10.1039/D2TB01875F

127. Mashinchian, O., et al., *Regulation of stem cell fate by nanomaterial substrates*. Nanomedicine, 2015. **10 5**: p. 829-47. DOI: 10.2217/nnm.14.225

128. Chueng, S.-T.D., et al., *Multidimensional nanomaterials for the control of stem cell fate*. Nano Convergence, 2016. **3.** DOI: 10.1186/s40580-016-0083-9

129. Yi, D.K., et al., *Recent progress in nanotechnology for stem cell differentiation, labeling, tracking and therapy.* Journal of Materials Chemistry. B, 2017. **5 48**: p. 9429-9451. DOI: 10.1039/C7TB02532G

130. Song, D. and Q. Xu, *Engineering a Nano/Biointerface for Cell and Organ-Selective Drug Delivery.* Langmuir: The ACS Journal of Surfaces and Colloids, 2022. DOI: 10.1021/acs.langmuir.2c01609

131. Sanchez-Cano, C., et al., *X-ray-Based Techniques to Study the Nano–Bio Interface*. ACS Nano, 2021. **15**: p. 3754 - 3807. DOI: 10.1021/acsnano.0c09563

132. Bondon, N., et al., *Nanodiamonds for bioapplications, recent developments*. Journal of Materials Chemistry. B, 2020. DOI: 10.1039/D0TB02221G

133. Epperla, C.P., H.-H. Lin, and H.-C. Chang, *Nanodiamonds and Their Biological Applications,* in *Carbon Nanostructures for Biomedical Applications.* 2021, The Royal Society of Chemistry. p. 257-292. DOI: 10.1039/9781839161070-00257

134. Alber, M., et al., *Integrating machine learning and multiscale modeling—perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences.* NPJ digital medicine, 2019. **2**(1): p. 115. DOI: 10.1038/s41746-019-0193-y

135. Siegenfeld, A.F. and Y. Bar-Yam, *An Introduction to Complex Systems Science and Its Applications*. Complexity. 2020: p. 6105872:1-6105872:16. DOI: 10.1155/2020/6105872

136. Wei, M., et al., *Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach*. International Journal of Nanomedicine, 2023. **18:** p. 611 - 626. DOI: 10.2147/IJN.S395010

137. Sushnitha, M., et al., *Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications.* Frontiers in Bioengineering and Biotechnology, 2020. **8**. DOI: 10.3389/fbioe.2020.00627

138. Borton, D.A., et al., *Developing Collaborative Platforms to Advance Neurotechnology and Its Translation.* Neuron, 2020. **108:** p. 286-301. DOI: 10.1016/j.neuron.2020.10.001

139. Wang, W.-D., et al., *Sniping Cancer Stem Cells with Nanomaterials.* ACS Nano, 2023. DOI: 10.1021/acsnano.3c07828

140. Bas, A.A., et al., *Understanding the Development, Standardization, and Validation Process of*

Alternative In Vitro Test Methods for Regulatory Approval from a Researcher Perspective. Small, 2021: p. e2006027. DOI: 10.1002/smll.202006027

141. Sansbury, B.E., et al., *Rigor Me This: What Are the Basic Criteria for a Rigorous, Transparent, and Reproducible Scientific Study?* Frontiers in Cardiovascular Medicine, 2022. **9**. DOI: 10.3389/fcvm.2022.913612

142. Tomaschek, R., et al., *Improvement Strategies for the Challenging Collaboration of General Practitioners and Specialists for Patients with Complex Chronic Conditions: A Scoping Review.* International Journal of Integrated Care, 2022. **22**. DOI: 10.5334/ijic.5970

143. Ramón y. Cajal, S., et al., *Clinical implications of intratumor heterogeneity: challenges and opportunities.* Journal of Molecular Medicine (Berlin, Germany), 2020. **98:** p. 161 - 177. DOI: 10.1007/s00109-020-01874-2

144. Ma, X., Z. Luan, and J. Li, *Inorganic Nanoparticles-Based Systems in Biomedical Applications of Stem Cells: Opportunities and Challenges.* International Journal of Nanomedicine, 2023. **18**: p. 143 - 182. DOI: 10.2147/IJN.S384343

145. Kim, T.K., et al., *Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.* Nature Reviews Drug Discovery, 2022. **21**: p. 529 - 540. DOI: 10.1038/s41573-022-00493-5

146. Bashraheel, S.S., A. Domling, and S.K. Goda, *Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.* Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2020. **125**: p. 110009. DOI: 10.1016/j.biopha.2020.110009

147. Tsimberidou, A.-M., et al., *Review of precision cancer medicine: Evolution of the treatment paradigm.* Cancer Treatment Reviews, 2020. **86:** p. 102019. DOI: 10.1016/j.ctrv.2020.102019

148. Alghamdi, M.A., et al., *The Promise of Nanotechnology in Personalized Medicine*. Journal of Personalized Medicine, 2022. **12**. DOI: 10.3390/jpm12050673

149. Li, J., et al., *The Growing Impact of Micro/Nanomaterial-Based Systems in Precision Oncology: Translating "Multiomics" Technologies.* Advanced Functional Materials, 2020. **30**. DOI: 10.1002/adfm.201909306

150. Assen, L., et al., *Recognizing the ethical implications of stem cell research: A call for broadening the scope*. Stem Cell Reports, 2021. **16:** p. 1656 - 1661. DOI: 10.1016/j.stemcr.2021.05.021

151. MacPherson, A. and J. Kimmelman, *Ethical development of stem-cell-based interventions*. Nature Medicine, 2019. **25**(7): p. 1037-1044. DOI: 10.1038/s41591-019-0511-6

152. Han, H., et al., *Engineered stem cell-based strategy: A new paradigm of next-generation stem cell product in regenerative medicine.* Journal of Controlled Release: Official Journal of the Controlled Release Society, 2023. DOI: 10.1016/j.jconrel.2023.12.024

153. Soleymani-Goloujeh, M., S. Hosseini, and M. Baghaban Eslaminejad, *Advanced Nanotechnology Approaches as Emerging Tools in Cellular-Based Technologies*. Advances in Experimental Medicine and Biology, 2022. DOI: 10.1007/5584_2022_725

154. Baracskay, D., *Technology Ethics in Public Service: Envisioning the Role of the Techno-Ethicist. Public Integrity,* 2022. **25:** p. 220 - 233. DOI: 10.1080/10999922.2022.2031505

155. Anklam, E., et al., *Emerging technologies and their impact on regulatory science.* Experimental

Biology and Medicine, 2021. **247**: p. 1 - 75. DOI: 10.1177/15353702211052280

156. Solarska-Ściuk, K. and H. Kleszczyńska, *Possibilities of nanodiamonds application – biological and medical aspects.* Acta Poloniae Pharmaceutica - Drug Research, 2019. DOI: 10.32383/appdr/109501

157. O'Brien, J., et al., *Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.* Therapeutic Innovation & Regulatory Science, 2020. **54:** p. 283 - 292. DOI: 10.1007/s43441-019-00055-9

158. Bretthauer, M., et al., *The New European Medical Device Regulation: Balancing Innovation and Patient Safety*. Annals of Internal Medicine, 2023. **176**: p. 844 - 848. DOI: 10.7326/M23-0454

159. Pizevska, M., et al., *Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective.* Frontiers in Medicine, 2022. **9**. DOI: 10.3389/fmed.2022.757647

160. Schermuly, A.C., A. Petersen, and A. Anderson, *'I'm not an activist!': digital self-advocacy in online patient communities.* Critical Public Health, 2020. **31:** p. 204 - 213. DOI: 10.1080/09581596.2020.1841116

161. Reining, S., et al., *Knowledge accumulation in design science research: ways to foster scientific progress*. ACM SIGMIS Database: The DATABASE for Advances in Information Systems, 2022. **53**(1): p. 10-24. DOI: 10.1145/3514097.3514100

162. Black, L.W., et al., *Building Positive Peace Through Dialogue and Deliberation*. Communication and Education: In Times of Crisis and Conflict, 2024: p. DOI: 10.1002/9781119985280.ch11

163. Tang, L., J. Li, and S. Fantus, *Medical artificial intelligence ethics: A systematic review of empirical studies.* Digital Health, 2023. **9.** DOI: 10.1177/20552076231186064

164. Wale, J.L., et al., *Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action.* Research Involvement and Engagement, 2021. **7**. DOI: 10.1186/s40900-020-00248-9

165. Anurogo, D. and N.A. Hidayat, *THE ART OF TELEVASCULOBIOMEDICINE 5.0*. 2023: Nas Media Pustaka.

166. Ehsani, A., et al., *Nanomaterials and Stem Cell Differentiation Potential: An Overview of Biological Aspects and Biomedical Efficacy.* Current Medicinal Chemistry, 2021. DOI: 10.2174/0929867328666210712193113

167. Malik, S., K. Muhammad, and Y. Waheed, *Emerging Applications of Nanotechnology in Healthcare and Medicine*. Molecules, 2023. **28**. DOI: 10.3390/molecules28186624

168. Zhang, C., et al., *Progress, challenges, and future of nanomedicine*. Nano Today, 2020. **35:** p. 101008. DOI: 10.1016/j.nantod.2020.101008

169. Sivandzade, F. and L. Cucullo, *Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview.* International Journal of Molecular Sciences, 2021. **22.** DOI: 10.3390/ijms22042153

170. Tariq, U., et al., *Role of Biomaterials in Cardiac Repair and Regeneration: Therapeutic Intervention for Myocardial Infarction*. ACS Biomaterials Science & Engineering, 2022. DOI: 10.1021/acsbiomaterials.2c00454

171. Mohamed, N.A., et al., *Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases*. International Journal of Molecular Sciences, 2022. **23.** DOI: 10.3390/ijms23031404

172. Iravani, S. and R.S. Varma, *Advanced Drug Delivery Micro-and Nanosystems for Cardiovascular Diseases*. Molecules, 2022. **27**(18): p. 5843. DOI: 10.3390/molecules27185843

173. Lee, J.-H., et al., Functional nanoarrays for investigating stem cell fate and function. Nanoscale, 2020. DOI: 10.1039/C9NR10963C

174. Debnath, S.K. and R. Srivastava, *Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects*. Frontiers in Nanotechnology, 2021. **3**: p. 644564. DOI: 10.3389/fnano.2021.644564

175. Saraf, J., et al., *Growing synergy of nanodiamonds in neurodegenerative interventions.* Drug Discovery Today, 2019. **24 2**: p. 584-594. DOI: 10.1016/j.drudis.2018.10.012

176. Pan, F., et al., *Recent advances in the structure and biomedical applications of nanodiamonds and their future perspectives.* Materials & Design, 2023. DOI: 10.1016/j.matdes.2023.112179

177. Church, D.L. and C. Naugler, *Using a systematic approach to strategic innovation in laboratory medicine to bring about change.* Critical Reviews in Clinical Laboratory Sciences, 2022. **59**: p. 178 - 202. DOI: 10.1080/10408363.2021.1997899

178. Miller, T., et al. EMPOWERING BIOLOGICAL SCIENCES THROUGH MACHINE LEARNING: INNOVATIONS, CHALLENGES, AND EDUCATIONAL IMPLICATIONS. In the 12th International scientific and practical conference "Actual issues of the development of science and ensuring the quality of education" (March 28–31, 2023) Florence, Italy. International Science Group. 2023. 428 p. 2023. DOI: 10.46299/ISG.2023.1.12

179. Bhatnagar, B., V. Dörfler, and J. MacBryde, *Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries.* The Journal of Technology Transfer, 2022: p. 1-45. DOI: 10.1007/s10961-022-09958-6

180. Alshangiti, D.M., et al., *Revolutionizing biomedicine: advancements, applications, and prospects of nanocomposite macromolecular carbohydrate-based hydrogel biomaterials: a review*. RSC advances, 2023. **13**(50): p. 35251-35291. DOI: 10.1039/D3RA07391B

181. Eger, J., *Untold Power: The Marriage of Art and Technology.* 2022: Common Ground Research Networks. DOI: 10.18848/978-0-949313-04-1/CGP

182. Anklam, E., et al., *Emerging technologies and their impact on regulatory science*. Experimental Biology and Medicine, 2022. **247**(1): p. 1-75. DOI: 10.1177/15353702211052280